Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research: ADA 2021
Dapagliflozin Use in Patients with COVID-19
Risk Reduction of Type 2 Diabetes after Gestational Diabetes
Infusion Set Survival and Performance of Medtronic Extended-Wear Infusion Set
MOST POPULAR ARTICLES OF THE MONTH
#1 Low-Calorie Mediterranean Diet vs. Low Carb Diet for Weight Loss
#2 Benefits for Patients with Type 1 Diabetes Using the New Omnipod® 5
Letter from the Editor
The recent ADA Scientific Sessions have been chock full of great information. It appears as if the Pandemic had no effect on research of devices and medications.
There was a lot of focus on the SGLT-2 Inhibitors and the multiple positive effects for diabetes patients. This week our intern, Alan Martinez from USF College of Pharmacy, looked at the research on the use of these medications to prevent the metabolic complications of the coronavirus. Check out the results by clicking here.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: FDA Approves Drug for Adults with Chronic Kidney Disease Associated with Type 2 Diabetes
The US Food and Drug Administration (FDA) approved finerenone (Kerendia), the first agent from a new class of nonsteroidal mineralocorticoid receptor antagonists (MRAs), on July 9 for treating patients with chronic kidney disease (CKD) associated with type 2 diabetes.
TOP STORIES — Diabetes News and Research
Dapagliflozin has shown clinical effectiveness in some of the same metabolic processes that are affected by COVID-19, but can it help treat patients who have contracted the virus?
The prevalence of underdiagnosed prediabetes and type 2 diabetes mellitus (T2DM) plays an active role in gestational diabetes.
Real-world data for the Medtronic Extended-Wear Infusion Set revealed at the 81st American Diabetes Association scientific session.